Vivoryon Therapeutics NV (AS:VVY) — Market Cap & Net Worth
Market Cap & Net Worth: Vivoryon Therapeutics NV (VVY)
Vivoryon Therapeutics NV (AS:VVY) has a market capitalization of $37.91 Million (€32.42 Million) as of August 27, 2026. Listed on the AS stock exchange, this Netherlands-based company holds position #23047 globally and #84 in its home market, demonstrating a -1.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vivoryon Therapeutics NV's stock price €1.12 by its total outstanding shares 29614337 (29.61 Million). Check Vivoryon Therapeutics NV stock quote for real-time trading data and today's change.
Vivoryon Therapeutics NV Market Cap History: 2015 to 2026
Vivoryon Therapeutics NV's market capitalization history from 2015 to 2026. Data shows change from $848.07 Million to $38.78 Million (-23.21% CAGR).
Index Memberships
Vivoryon Therapeutics NV is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
AMS Small Cap
ASCX
|
$12.59 Billion | 0.30% | #20 of 21 |
Weight: Vivoryon Therapeutics NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vivoryon Therapeutics NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vivoryon Therapeutics NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check VVY net asset value to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
-77.85x
Vivoryon Therapeutics NV's market cap is -77.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $657.82 Million | $10.76 Million | -$12.65 Million | 61.11x | N/A |
| 2023 | $281.83 Million | $-3.62 Million | -$28.34 Million | -77.85x | N/A |
Competitor Companies of VVY by Market Capitalization
Companies near Vivoryon Therapeutics NV in the global market cap rankings as of August 27, 2026. Also see Vivoryon Therapeutics NV cash conversion from operations for how efficiently the company converts equity into cash flow.
Key companies related to Vivoryon Therapeutics NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #322 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #460 globally with a market cap of $59.61 Billion USD ( AU$84.24 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #554 globally with a market cap of $49.72 Billion USD ( ₩73.37 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $552.85 |
| #322 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $833.56 |
| #460 | CSL Ltd | AU:CSL | $59.61 Billion | AU$173.64 |
| #554 | Samsung Biologics Co Ltd | KO:207940 | $49.72 Billion | ₩1585000.00 |
Vivoryon Therapeutics NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Vivoryon Therapeutics NV's market cap moved from $848.07 Million to $ 38.78 Million, with a yearly change of -23.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €38.78 Million | -21.13% |
| 2025 | €49.16 Million | -28.64% |
| 2024 | €68.90 Million | -75.55% |
| 2023 | €281.83 Million | -21.12% |
| 2022 | €357.30 Million | -45.68% |
| 2021 | €657.82 Million | +110.88% |
| 2020 | €311.95 Million | +65.62% |
| 2019 | €188.35 Million | +112.50% |
| 2018 | €88.63 Million | -75.85% |
| 2017 | €367.00 Million | -41.19% |
| 2016 | €624.07 Million | -26.41% |
| 2015 | €848.07 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 26th, 2026 the market cap of Vivoryon Therapeutics NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.91 Million USD |
| MoneyControl | $37.91 Million USD |
| MarketWatch | $37.91 Million USD |
| marketcap.company | $37.91 Million USD |
| Reuters | $37.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more